News: Host-Tumor Interactions Research Program

A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.

Mariana Byndloss, DVM, PhD, assistant professor of Pathology, Microbiology and Immunology, has received a V Scholar Award from the V Foundation for Cancer Research.

Continuous activation of cell surface receptors increases signaling that can promote oncogenic transformation. One receptor, EphA2, has been identified as a driver of lung cancer, but its interacting partners are not well characterized.

Ann Richmond, PhD, Ingram Professor of Cancer Research, is the 2019 recipient of the Society for Leukocyte Biology Legacy Award.

GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.

Jeffrey Rathmell, PhD, is a 2019 recipient of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity.

Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.

A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.

The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.